GeneDx Holdings (WGS): Holding Near $88 After Mid-September Rally and Guidance Revision
Key Takeaways
- GeneDx Holdings (WGS) shares finished the past 30 days roughly flat near $88, after rallying above $100 in mid-September before pulling back on elevated volume.
- The company is a leader in whole exome and genome sequencing for pediatric and rare disease diagnosis, powered by its GeneDx Infinity genomic dataset.
- Management lowered full-year 2026 revenue guidance to $475–$490 million, citing lower average reimbursement rates and pressure in non-core business lines.
- Second-quarter 2026 exome and genome volume grew 32% year over year, and adjusted net income turned modestly positive, although GAAP losses persist.
- Multiple sell-side analysts trimmed price targets, and securities litigation tied to the Fabric Genomics acquisition remains an overhang on sentiment.
Market Snapshot for WGS
GeneDx Holdings trades on the Nasdaq with a market capitalization around $3 billion and a 52-week range spanning roughly $32 to $171, underscoring the stock's volatility over the past year. During the 30-day window ending in late September 2026, WGS shares moved within a wide band: they held near the high-$80s through late August, climbed to an intraday peak above $100 by mid-September, and then retraced to the high-$80s, leaving the stock little changed on a net basis over the period.
The pullback reflected a market digesting both strong underlying diagnostic demand and renewed concerns about reimbursement rates, guidance revisions, and legal exposure. Sector-wide sentiment in genomics and precision medicine remains constructive but selective, with investors rewarding companies that can demonstrate durable revenue growth while progressing toward consistent profitability. From what I see, this kind of consolidation often sets up clearer signals for the quarters ahead.
GeneDx's Business and Competitive Position
GeneDx Holdings Corp. is a genomics company focused primarily on pediatric and rare disease diagnostics. Its core offerings, the ExomeDx and GenomeDx tests, use whole exome and whole genome sequencing to deliver precise, faster diagnoses for patients with rare and ultra-rare genetic conditions. The company also provides data and information services to biopharma partners and develops an AI-based platform for sequencing analysis, interpretation, and clinical reporting.
A central competitive asset is GeneDx Infinity, described by the company as one of the world's largest rare disease genomic datasets, comprising nearly one million exomes and genomes alongside more than 2.5 million genetic tests. This data foundation supports both clinical diagnostics and AI-driven discovery. GeneDx competes with other genetic testing and diagnostics providers such as Natera (NTRA) in the broader molecular diagnostics landscape, while differentiating itself through its focus on rare disease and its deep, phenotype-rich dataset. I also checked comparable names using Tickeron’s AI Screener to see how the stock stacks up on key metrics.
Recent Developments Shaping WGS
Several verified developments have shaped WGS investor sentiment in recent months. In the first quarter of 2026, exome and genome test volumes grew 34% year over year, but revenue fell short of expectations because of lower average reimbursement rates and underperformance in non-core segments. In response, management reduced full-year 2026 revenue guidance to $475–$490 million from an earlier $540–$555 million range, and lowered expected exome and genome revenue growth.
Second-quarter 2026 results offered a more balanced picture. Exome and genome volume increased 32% year over year, with related revenue reaching approximately $100 million, and adjusted gross margin held at about 70%. Adjusted net income returned to slightly positive territory, though the company still reported a GAAP net loss of roughly $17.7 million for the quarter.
The revised guidance prompted a wave of price-target reductions. Craig-Hallum lowered its target to $85 from $153, BTIG to $90 from $170, and Guggenheim to $70 from $100, while TD Cowen trimmed its target to $55 from $60. Separately, the company's acquisition of Fabric Genomics has drawn scrutiny, with securities class actions filed in mid-2026 alleging misleading disclosures related to the transaction. One thing that stands out here is how quickly sentiment can shift when guidance and legal matters intersect.
2026 Outlook and Factors to Monitor
Looking ahead, investors are likely to focus on whether GeneDx can sustain double-digit growth in exome and genome volumes while stabilizing average reimbursement rates. Upcoming quarterly results and any updates to guidance will be closely monitored, as will progress toward consistent adjusted profitability and free cash flow generation.
Additional factors worth watching include the expansion of payer coverage across state Medicaid programs and commercial insurers, adoption of genome sequencing in neonatal intensive care and prenatal settings, and the evolution of the AI-driven interpretation platform. The resolution or progression of securities litigation related to the Fabric Genomics acquisition, along with broader macroeconomic pressures on healthcare utilization and reimbursement, also remain important variables that could influence the stock's trajectory. I’m watching this closely as the next few quarters could clarify the path forward.
Exploring Systematic Approaches with AI Tools
When evaluating names like WGS, I sometimes review Tickeron's Trending AI Robots to see how different algorithmic strategies align with the stock's volatility profile and sector dynamics. These bots offer a range of timeframes and risk parameters that can complement fundamental research without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
WGS in downward trend: price dove below 50-day moving average on September 29, 2026
WGS moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend. In 27 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WGS as a result. In 65 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for WGS turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 35 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
The 10-day moving average for WGS crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where WGS's RSI Indicator exited the oversold zone, 28 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for WGS moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +7.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where WGS advanced for three days, in 235 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
WGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 169 of 193 cases where WGS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. WGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.493) is normal, around the industry mean (72.578). WGS has a moderately high P/E Ratio (739.818) as compared to the industry average of (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (6.270) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement